Form 4: Axsome CEO Exercises, Sells Shares Under 10b5-1 Plan

Axsome Therapeutics CEO Herriot Tabuteau exercised stock options and subsequently sold the acquired shares as part of a pre-approved 10b5-1 plan.

Summary

• Herriot Tabuteau, CEO, Director, and 10% Owner of Axsome Therapeutics, Inc. (AXSM), reported multiple transactions involving company common stock.
• Transactions occurred on October 6, 7, and 8, 2025, and were executed pursuant to a pre-approved Rule 10b5-1 plan.
• The exercises were necessary due to stock options nearing their 10-year expiration date of May 27, 2026.
• On October 6, 2025, 19,220 shares were acquired through option exercise at $8.02 per share and subsequently sold at a weighted average price of $120.17.
• On October 7, 2025, 13,390 shares were acquired through option exercise at $8.02 per share and subsequently sold at a weighted average price of $118.77.
• On October 8, 2025, 12,774 shares were acquired through option exercise at $8.02 per share and subsequently sold at a weighted average price of $118.84.
• Following these transactions, direct beneficial ownership of common stock is 7,229 shares.
• Indirect beneficial ownership remains at 7,344,500 shares, held by an entity where the reporting person has voting and dispositive power.
• The number of derivative securities (stock options) beneficially owned decreased from 474,300 to 415,736 after these exercises.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine insider transaction (exercise of expiring options and subsequent sale) conducted under a pre-approved 10b5-1 plan, which is a common and compliant practice. It does not indicate a change in company fundamentals or management's outlook.

Positives

• The CEO realized significant gains from the exercise of stock options, indicating a substantial increase in the company's stock price since the options were granted.
• Transactions were conducted under a pre-approved 10b5-1 plan, demonstrating a structured and compliant approach to insider trading.
• The exercise of options was due to their impending expiration, which is a routine event for executives managing their equity compensation.

Negatives

• The transactions represent insider selling, which, while planned, reduces the direct beneficial ownership of the CEO in the company's common stock.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the inherent market risks associated with holding equity securities.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The exercise of stock options was a 'necessary exercise' due to the attainment of the 10-year expiration date of such options.
• All reported transactions were executed 'pursuant to a pre-approved 10b5-1 plan'.

Industry Context

This filing is a routine disclosure of insider transactions and does not provide information related to broader industry trends or competitive landscape. It is specific to the equity compensation management of Axsome Therapeutics' CEO.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for insider transactions is a standard practice among public company executives to manage equity compensation while adhering to insider trading regulations.
• The exercise of expiring stock options is a common event for executives, particularly as options approach their 10-year term, and is consistent with typical equity compensation structures in the pharmaceutical industry.

Corporate Governance

Related Party Transactions

• The reported transactions are insider dealings by the CEO, Director, and 10% Owner, which are a form of related party transaction. These are disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO could be perceived negatively by some, but the pre-planned nature and reason (expiring options) mitigate concerns about management's confidence. The transactions represent a realization of compensation gains.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 reports routine insider transactions involving the exercise of expiring stock options and subsequent sale of shares under a pre-approved 10b5-1 plan. While it represents insider selling, the pre-planned nature and reason for exercise (option expiration) suggest it is not indicative of a change in management's outlook on the company's fundamentals. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Transaction, Stock Options, 10b5-1 Plan, CEO, Stock Sale, Beneficial Ownership